CMS hospital readmission reduction program and anticoagulants received following a THA/TKA discharge.

CONCLUSIONS: Rivaroxaban treatment post-THA/TKA discharge reduced the risk of 30-day readmission compared to non-anticoagulants. Simulations illustrated that increasing rivaroxaban use could decrease the HRRP penalty. PMID: 29749269 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research